Oramed Pharmaceuticals Total Assets 2011-2026 | ORMP

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Oramed Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
231 M	155 M	221 M	162 M	178 M	44.6 M	34.7 M	47.4 M	38.7 M	42.8 M	26.4 M	21.8 M	8.66 M	5.29 M	4.33 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
231 M	4.33 M	81.4 M

Quarterly Total Assets Oramed Pharmaceuticals

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
220 M	162 M	148 M	155 M	165 M	184 M	204 M	221 M	231 M	156 M	160 M	162 M	164 M	162 M	172 M	178 M	128 M	80.5 M	182 M	41 M	44.6 M	44.6 M	44.6 M	31.1 M	34.7 M	34.7 M	34.7 M	43.6 M	47.4 M	47.4 M	47.4 M	41.5 M	38.7 M	38.7 M	38.7 M	44.9 M	42.8 M	42.8 M	42.8 M	23.9 M	26.4 M	26.4 M	26.4 M	24.6 M	21.8 M	21.8 M	21.8 M	8.01 M	8.66 M	8.66 M	8.66 M	6.82 M	5.29 M	5.29 M	5.29 M	3.9 M	4.33 M	4.33 M	4.33 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
231 M	3.9 M	73.4 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
BioLineRx Ltd. BLRX	38.9 M	$ 2.25	1.81 %	$ 908 M	Israel
BioNTech SE BNTX	22 B	$ 91.28	0.11 %	$ 27.2 B	Germany
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
Alnylam Pharmaceuticals ALNY	4.97 B	$ 330.34	3.6 %	$ 43.3 B	USA
CollPlant Biotechnologies Ltd. CLGN	18.7 M	$ 0.44	-16.64 %	$ 5.04 M	Israel
I-Mab IMAB	6.33 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	151 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
Catalyst Pharmaceuticals CPRX	1.1 B	$ 24.98	1.17 %	$ 3.05 B	USA
Midatech Pharma plc MTP	14.8 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
Corbus Pharmaceuticals Holdings CRBP	168 M	$ 10.14	-0.29 %	$ 135 M	USA
Cardiff Oncology CRDF	61.9 M	$ 1.58	-	$ 106 M	USA
Curis CRIS	20 M	$ 0.53	-3.07 %	$ 6.98 M	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Crinetics Pharmaceuticals CRNX	1.13 B	$ 37.7	1.26 %	$ 3.55 B	USA
CRISPR Therapeutics AG CRSP	2.27 B	$ 49.15	-0.73 %	$ 4.42 B	Schweiz
Adverum Biotechnologies ADVM	180 M	-	-	$ 86.2 M	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Anavex Life Sciences Corp. AVXL	104 M	$ 2.96	-1.0 %	$ 252 M	USA
Applied Molecular Transport AMTI	107 M	-	-	$ 10.1 M	USA
Aeterna Zentaris AEZS	35.1 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	6.95 M	-	-10.17 %	$ 12.2 K	USA
AIkido Pharma AIKI	113 M	-	1.93 %	$ 17.4 M	USA
Aeglea BioTherapeutics AGLE	778 M	-	-	$ 1.01 B	USA
CytomX Therapeutics CTMX	152 M	$ 4.4	-3.51 %	$ 607 M	USA
Applied Genetic Technologies Corporation AGTC	66.7 M	-	-	$ 26.5 M	USA
Akero Therapeutics AKRO	826 M	-	-	$ 3.67 B	USA
Akouos AKUS	279 M	-	0.23 %	$ 488 M	USA
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
Citius Pharmaceuticals CTXR	117 M	$ 0.86	0.67 %	$ 5.79 M	USA
Cue Biopharma CUE	42.2 M	$ 0.18	-1.61 %	$ 17.1 M	USA
Allena Pharmaceuticals ALNA	34.8 M	-	3.16 %	$ 1.9 M	USA
Alpine Immune Sciences ALPN	287 M	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	24.2 M	-	10.36 %	$ 9.8 M	USA
Aquestive Therapeutics AQST	160 M	$ 4.09	-0.97 %	$ 437 M	USA
Cyclerion Therapeutics CYCN	9.58 M	$ 4.15	-32.52 %	$ 10.4 M	USA
Daré Bioscience DARE	32.5 M	$ 1.81	4.02 %	$ 20.2 M	USA
DBV Technologies S.A. DBVT	234 M	$ 20.36	-3.32 %	$ 2.84 B	France
Aravive ARAV	62.2 M	-	-13.39 %	$ 1.45 M	USA
Arcturus Therapeutics Holdings ARCT	271 M	$ 8.22	2.37 %	$ 225 M	Israel
Aptose Biosciences APTO	10 M	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	66.7 M	-	-39.0 %	$ 4.57 M	USA
Denali Therapeutics DNLI	1.37 B	$ 19.38	-6.15 %	$ 3.19 B	USA
Dyadic International DYAI	9.95 M	$ 0.87	-2.8 %	$ 31.5 M	USA
CureVac N.V. CVAC	1.16 B	-	-	$ 867 M	Germany
AstraZeneca PLC AZN	114 B	-	-	$ 96.9 B	Britain
Celldex Therapeutics CLDX	583 M	$ 31.37	1.0 %	$ 2.08 B	USA
Avenue Therapeutics ATXI	2.93 M	-	-52.27 %	$ 4.45 M	USA